Lilly to Launch Mounjaro Pen in India to Compete with Novo’s Wegovy

Lilly to launch Mounjaro pen in India as Novo rivalry heats up in mega market

In battle for Indian anti-obesity market, Eli Lilly’s pre-filled pen on one side, Novo Nordisk’s on other

India's anti-obesity drug market is currently valued at Rs 3,000-3,500 crore & is projected to grow nearly eightfold by 2030, according to market estimates.

Lilly to launch Mounjaro pen in India to compete with Novo’s Wegovy

By Rishika Sadam HYDERABAD (Reuters) -Eli Lilly said on Thursday India’s drug regulator had approved the launch of pre-filled injector pens of its blockbuster weight-loss drug, Mounjaro, giving it more options to compete with Novo Nordisk’s recently launched Wegovy. Lilly started selling Mounjaro in India in late March for diabetes and obesity, and it was so far available only in vials and in 2.5 mg and 5 mg doses. The competition in the world’s…

Suzanne Harrington: I have been on Mounjaro for three months — here's what happened

Three months since Suzanne Harrington was prescribed the weight-loss jab Mounjaro, she opens up her diary and reveals all

Can 2 blockbuster weight loss injectables, Wegovy & Mounjaro, fight India’s obesity curve? Listen in to the experts

Know all about drug efficacy, side effects, decades of research and who needs to take it, who doesn’t

Lilly to launch Mounjaro pen in India to compete with Novo's Wegovy